Compare Regeneron Pharmaceuticals Inc (REGN) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs 22nd Century Group Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $741.17 (market cap $76.14B), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 122476.6× 22nd Century Group Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and 22nd Century Group Inc for 32 Days on average.
| REGN | XXII | |
|---|---|---|
Market Cap | $76.14B | $621.67K |
Volume | 500,239 | 45,625 |
Sector | Health | Consumer Staples |
52-Week High | $852.03 | $483.00 |
52-Week Low | $557.73 | $0.80 |
Typical Hold Time | 107 Days | 32 Days |
Enterprise Value | $70.85B | -$3.69M |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $746.54, up 0.6% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments. Cash flow improved in 2025, and profitability remains robust with a net income margin of 27.86%.
The outlook is positive, driven by the expanded Sanofi partnership and promising clinical trial updates, though technical indicators suggest near-term resistance. Risks include competitive pressures in key drug markets and reliance on successful drug development. Analysts are bullish with a consensus price target of $849.84, indicating potential upside from current levels.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
